Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Negative equity NBB
More debt than assets in 1 of the last 4 fiscal years.
-
Tight liquidity NBB
Cash and receivables cover 46 % of short-term debt in 2025; threshold 65 %.
Financials
Financial year 2025
PHARMIX from Wuustwezel, company number BE0421297724, closed financial year 2025 with a result of € -475,283 after tax. For that financial year PHARMIX recorded a gross margin of € -370,159 and equity of € -348,800. Compared with financial year 2024, the result moved from € 274,428 to € -475,283. The company made a loss. More debts than assets. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on July 31, 2026.
€ -348,800
▼ € 475,448 vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -475,283
▼ still € 274,428 profit in 2024
Profit after tax over the fiscal year.
€ 99,582
▼ 77% vs 2024
Cash and bank balances on the last day of the fiscal year.
Loss, nothing to pay out
Reserves fell to € -373,800.
People and assets in 2025
0
Average over the fiscal year, from the social balance sheet.
€ 15,138
▲ 48% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
€ 740,669
▼ 6% vs 2024
€ 94,075 is repaid this year. At this pace the long-term loan is gone in ≈ 8 years.
€ 70,332
▼ 44% vs 2024
Supplier invoices still open on the last day of the fiscal year.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 53,385 | € 53,852 | € 478,643 | € -370,159 | ▼ € 848,802 |
| Profit after taxes | € -30,000 | € -34,951 | € 274,428 | € -475,283 | ▼ € 749,710 |
| Equity | € 87,171 | € 52,220 | € 126,648 | € -348,800 | ▼ € 475,448 |
| Total debts | € 1,022,437 | € 956,177 | € 1,155,413 | € 990,932 | ▼ 14% |
| Cash | € 256,164 | € 271,291 | € 432,889 | € 99,582 | ▼ 77% |
| Land & buildings | € 162,532 | € 121,459 | € 86,870 | € 68,984 | ▼ 21% |
| Retained profit | € 62,171 | € 27,220 | € 101,648 | € -373,800 | ▼ € 475,448 |
| Dividend | € 800,000 | € 0 | € 200,000 | € 0 | ▼ 100% |
| Bank debt | € 673,822 | € 827,090 | € 787,766 | € 740,669 | ▼ 6% |
| Balance sheet total | € 1,109,608 | € 1,008,397 | € 1,282,060 | € 642,132 | ▼ 50% |
Key figures of PHARMIX, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to PHARMIX?
What happened at PHARMIX in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: loss of € 475,283 (▼ € 749,710 vs 2024). Source: NBB ↗
- Nathyx became a director. NBB
- New establishment in Wuustwezel. KBO
- Start of the company according to the CBE. KBO
In short
From € 30,000 loss in 2022 to € 475,283 loss in 2025.
Paid € 67,933 in corporate taxes since 2022.
Best year ever: 2024, with € 274,428 profit.
Paid out € 1 million in dividends to the owners in total.
A new publication or filing at PHARMIX? We notify you, reason included.
Follow PHARMIXDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
The stake of Nathyx comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.
PHARMIXBehind PHARMIX is Nathyx. The shares are held by Nathyx (100%).
Establishments
Establishment units
Physical locations of this company
Verbrand-Hofstraat 26
2990 Wuustwezel
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Website
Technologies
Hosting & Email
Email provider
Microsoft 365
Hosting
CLDIN-NL Your Hosting B.V. part of Your.Online, NL
Website info
Features
Security
Details
- Company number
- 0421.297.724
- VAT number
- BE 0421.297.724
- Registered office
- Verbrand-Hofstraat 26, 2990 Wuustwezel
- Names & denominations
- PHARMIX
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 18 February 1981
- Peppol
- Active · Active since 1 Jan 2001
- Contact
- pharmix.be
- Activities · NACE
Groothandel in andere voedingsmiddelen, neg
Overige gespecialiseerde groothandel in voedingswaren